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Abstract
Objectives: Sildenafil citrate, a specific phosphodiesterase-5 inhibitor, is increasingly used for
pulmonary hypertension in pregnancy. Sildenafil is also emerging as a potential candidate for the
treatment of intra-uterine growth retardation and for premature labor. Its effects in the feto-
placental circulation are not known. Our objectives were to determine whether
phosphodiesterase-5 is present in the human feto-placental circulation, and to characterize the
effects and mechanisms of action of sildenafil citrate in this circulation.
Study Design: Ex vivo human chorionic plate arterial rings were used in all experiments. The
presence of phosphodiesterase-5 in the feto-placental circulation was determined by western
blotting and immunohistochemical staining. In a subsequent series of pharmacologic studies, the
effects of sildenafil citrate in pre-constricted chorionic plate arterial rings were determined.
Additional studies examined the role of cGMP and nitric oxide in mediating the effects of sildenafil.
Results: Phosphodiesterase-5 mRNA and protein was demonstrated in human chorionic plate
arteries. Immunohistochemistry demonstrated phosphodiesterase-5 within the arterial muscle
layer. Sildenafil citrate produced dose dependent vasodilatation at concentrations at and greater
than 10 nM. Both the direct cGMP inhibitor methylene blue and the cGMP-dependent protein
kinase inhibitor Rp-8-Br-PET-cGMPS significantly attenuated the vasodilation produced by sildenafil
citrate. Inhibition of NO production with L-NAME did not attenuate the vasodilator effects of
sildenafil. In contrast, sildenafil citrate significantly enhanced the vasodilation produced by the NO
donor sodium nitroprusside.
Conclusion: Phosphodiesterase-5 is present in the feto-placental circulation. Sildenafil citrate
vasodilates the feto-placental circulation via a cGMP dependent mechanism involving increased
responsiveness to NO.
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Background
Sildenafil citrate, a specific phosphodiesterase-5 inhibitor,
has demonstrated considerable promise as a pulmonary
vasodilator [1-4]. Sildenafil has been proposed as a poten-
tially useful therapy for pulmonary hypertension in preg-
nancy, a disease characterized by poor maternal and fetal
outcome [5,6]. Several case reports of its use in pregnant
patients with pulmonary hypertension have been pub-
lished to date [7,8]. The effects of sildenafil citrate on the
pulmonary vasculature and on pulmonary artery pressure
are increasingly well understood. Sildenafil citrate acts by
reducing cGMP breakdown, making pulmonary vascular
smooth muscle more sensitive to both endogenous and
exogenous NO, reducing ventilation/perfusion mismatch
and hypoxia [1,9,10].
Sildenafil is also emerging as a potential candidate for the
treatment of intra-uterine growth retardation and for pre-
mature labor [11]. Sildenafil has also been proposed as a
potential therapeutic strategy to maintain placental func-
tion in pre-eclampsia [12]. While placental transfer of
sildenafil citrate has not been quantified, due to its chem-
ical characteristics it is likely to easily cross the placenta
into the fetus. Should sildenafil citrate possess vasodila-
tory effects in the feto-placental circulation, this would
significantly enhance its therapeutic potential in the set-
ting of placental insufficiency. Of interest, sildenafil cit-
rate has recently been demonstrated not to alter the
contractile response to vasoconstrictors or to endothelial
dependent vasodilators[13]. However, the direct effects of
sildenafil citrate in the feto-placental circulation have not
been determined.
The purposes of these studies were to determine whether
the phosphodiesterase-5 enzyme was present in the feto-
placental circulation, and then to characterize the effects
and mechanisms of action of sildenafil citrate in this cir-
culation.
Methods
Following approval by the Galway University Hospitals
Clinical Research Ethical Committee, and written
informed patient consent, term placentae were obtained
following both vaginal and elective cesarean delivery
under regional anesthesia from patients following normal
pregnancy. None of the patients from whom the samples
were taken received general anesthesia for delivery. Exclu-
sion criteria included intra-uterine growth retardation,
pre-eclampsia, and patients with pregnancy induced
hypertension, hepatitis and HIV.
In all studies, umbilical arteries and their branches were
identified as they spread out onto the chorionic plate of
the placenta. Samples of the second-generation (second-
order) chorionic plate arteries were taken within 120 min-
utes of delivery and placed directly into ice-cold pyrogen-
free physiologic saline solution (122.6 mM NaCl, 5.4 mM
KCl, 20 mM NaHCO3, 0.8 mM MgSO4, 0.9 mM
Na2HPO4, 2.4 mM CaCl2 and 5.5 mM glucose) or flash
frozen depending on the experimental requirements.
Characterization of Phosphodiesterase-5
RT-PCR detection of Phosphodiesterase-5 mRNA
Freshly dissected chorionic plate arterial rings were
homogenized in Tri-Reagent (Sigma Aldrich, Poole, Dor-
set, United Kingdom) using a TissueRuptor (Qiagen,
Crawley, United Kingdom). RNA was then isolated as pre-
viously described [14]. RNA concentration was assessed
using a ND-1000 Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE USA), and 1 μg used to gener-
ate complementary DNA (cDNA) using an Access RT-PCR
kit (Promega UK, Southampton, United Kingdom).
Polymerase chain reaction was performed on the resulting
cDNA in a DNA Engine thermal cycler (Bio-Rad Laborato-
ries, Hercules, CA, USA). Detection primers used were:
Lamin A/C control: forward 5'-ATGGAGACCCCGTC-
CCAG-3'
reverse 5'-AGCTATCAGGTCACCCTCCTT-3'
PDE-5: forward 5'-TGGTCAATGCATGGTTTGCT-3'
reverse 5'-TCAGTCCATGGATATGCAAGA-3'
PCR products were analyzed on a 1% agarose (w/v) TAE
gel and imaged using GeneSnap image acquisition soft-
ware (Syngene, Cambridge, United Kingdom).
Western blot detection of Phosphodiesterase-5 Protein
Freshly dissected chorionic plate arterial rings were
homogenized in ice-cold PBS, at 100 mg per mL, using a
TissueRuptor (Qiagen). Samples were sonicated, and cen-
trifuged at 14000 g for 5 minutes to remove insoluble pro-
teins. SDS-PAGE sample buffer was added to various
volumes of lysate and samples electrophoresed on a 4–
20% acrylamide gel. Protein was transferred to nitrocellu-
lose and probed using a mouse monoclonal PDE-5 anti-
body (Clone number H00008654-M01, Abnova, Walnut,
CA, USA).
Immunohistochemical demonstration of Phosphodiesterase-5
Freshly dissected chorionic plate arterial rings were snap
frozen in isopentane and embedded in OCT and sec-
tioned to 15 μM thickness on glass slides as previously
described [15]. Sections were permeabilized with 0.3%
triton-PBS (v/v), and probed using PDE-5 primary
(Abnova) and phycoeryhtrin labeled secondary (Sigma
Aldrich) antibodies. Coverslips were sealed to the slides
with Hardset DAPI (Vector Laboratories, Servion, Switzer-Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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land) mounting medium, and images taken under fluo-
rescent microscopy. The coverslip was later removed and
the section stained with haematoxylin and eosin to dem-
onstrate ring structure.
Effects and mechanism of action of sildenafil
All studies, conducted in four separate series of experi-
ments, followed a randomized, controlled, paired design.
In each experiment, 4 chorionic rings, each 3 mm in
length, from a single chorionic plate artery were isolated,
mounted in physiologic saline solution at 37°C, and
equilibrated with 95% O2 – 5% CO2 in tissue baths (10 ml
capacity) as previously described [16,17] (Figure 1). Sam-
ples of the solution were intermittently analyzed for PO2,
PCO2 and pH, using an automated blood-gas analyzer
(ABL500, Radiometer Copenhagen, Denmark). Rings
were threaded onto a horizontally fixed platinum surgical
wire (150 μm diameter). A second hook, connected to an
isometric force transducer, was then passed through the
lumen of the ring (Figure 1). Isometric tension was
recorded as a function of time using a transducer system
(Grass FT03, Quincy, MA).
Baseline Interventions
Following a 60 minute equilibration period, an optimal
pre-tension of 2.00 g for each chorionic plate arterial ring
was utilized. These pretensions were determined in pre-
liminary experiments in our laboratory to elicit active ten-
sions of 80–100% of the maximum in each ring. Priming
contractions were induced by exposing the rings three
times to 80 mM KCl solution (iso-osmotically substituted
for NaCl), and pre-tension re-established at the end of
each five minute exposure by rinsing with physiologic
Schematic representation of the ex vivo incubation model system used in the isolated vessel experiments Figure 1
Schematic representation of the ex vivo incubation model system used in the isolated vessel experiments.Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
Page 4 of 10
(page number not for citation purposes)
saline solution. The paired preparations were then rand-
omized to group allocation.
Experimental Design and Interventions
Series 1 examined the direct effects of sildenafil citrate on
pre-constricted chorionic plate arterial rings. The rings
were first submaximally pre-constricted with U46619
(9,11-dideoxy-11alpha, 9alpha-epoxymethanoprostagla-
din F2α, 5 × 10-6 M), a thromboxane analog. This concen-
tration was demonstrated in preliminary experiments to
reliably produce a contraction of approximately 70% of
the maximum amplitude obtainable. Once a stable pla-
teau contractile response was obtained, the rings were
allowed to remain at plateau for 30 minutes. Two rings
from each placenta were then randomly assigned to
receive sildenafil citrate or vehicle. A cumulative concen-
tration response curve for sildenafil citrate (10-10 to 10-3
M) or vehicle was then constructed. The effects of sildena-
fil citrate were measured by calculating the mean ampli-
tude of selected areas for the final 5 minutes of each 15
minute interval.
Series 2 examined the potential for direct inhibition of
cGMP to attenuate sildenafil citrate induced vasorelaxa-
tion. Following pre-constriction with U46619, methylene
blue (3 × 10-5 M) a direct inhibitor of cGMP, was added to
one sildenafil citrate exposed bath and one control bath,
and vehicle added to the remaining baths. Following
equilibration for 20 minutes, a cumulative concentration
response curve for sildenafil citrate (10-7 to 10-3 M) or
vehicle was constructed. This resulted in a four group
design: (1) control with vehicle; (2) control with methyl-
ene blue; (3) sildenafil citrate with vehicle; (4) sildenafil
citrate with methylene blue.
Series 3 examined the potential for direct inhibition of
the cGMP-dependent protein kinase to attenuate sildena-
fil citrate induced vasorelaxation. In Series 3A, following
pre-constriction with U46619, two rings from each pla-
centa were then randomly assigned to undergo pre-incu-
bation with Rp-8-Br-PET-cGMPS (3 μM) or vehicle. A
cumulative concentration response curve for sildenafil cit-
rate (10-7 to 10-3 M) or vehicle was then constructed. This
resulted in a four group design: (1) control with vehicle;
(2) control with Rp-8-Br-PET-cGMPS; (3) sildenafil citrate
with vehicle; (4) sildenafil citrate with Rp-8-Br-PET-
cGMPS.
In Series 3B, following pre-constriction, two rings from
each placenta were then randomly assigned to undergo
pre-incubation with Rp-8-Br-PET-cGMPS (30 μM) or vehi-
cle. A cumulative concentration response curve for silde-
nafil citrate (10-7  to 10-3  M) or vehicle was then
constructed. This resulted in a four group design: (1) con-
trol with vehicle; (2) control with Rp-8-Br-PET-cGMPS;
(3) sildenafil citrate with vehicle; (4) sildenafil citrate
with Rp-8-Br-PET-cGMPS.
Series 4 examined the role of nitric oxide (NO) in mediat-
ing the relaxant effect of sildenafil citrate. The vasorelax-
ant effect of sildenafil citrate may be mediated via the
generation of NO or via an increase in sensitivity to NO.
Series 4A determined the potential for sildenafil citrate to
produce vasorelaxation via NO generation. Two rings
from each placenta were randomly assigned to undergo
20 minute pre-incubation with ω-nitro-L-arginine methyl
ester (L-NAME, 1 × 10-3 M), a non-specific inhibitor of
Nitric Oxide synthase (NOS), or vehicle. A cumulative
concentration response curve for sildenafil citrate (10-7 to
10-3 M) or vehicle was then constructed. This resulted in a
four group design: (1) control; (2) L-NAME; (3) sildenafil
citrate with vehicle; (4) sildenafil citrate with L-NAME.
Series 4B examined the potential for sildenafil citrate to
produce relaxation via an increase in sensitivity to NO.
One ring from each placenta was randomly assigned to
undergo pre-incubation with vehicle, sildenafil citrate
(10-8 M), and sildenafil citrate (10-6 M) respectively, in a
three group design. Following pre-constriction with
U46619, sildenafil citrate (10-8 M and 10-6 M) or vehicle
was then added to each bath and allowed to equilibrate
for 20 minutes. A cumulative concentration response
curve for sodium nitroprusside, an NO donor, in half log
increments from 10-9 to 10-8 M was then constructed.
End Protocol Contractility Assessment
At the end of each experimental protocol, pre-tension was
re-established by rinsing with physiologic saline solution.
A recovery time of 30 minutes was then allowed. The con-
tractile response to 80 mM KCl was then reassessed in
order to assess performance over the course of the experi-
ment. A final exclusion criterion was applied at this point,
with data from all four rings excluded from analysis if the
maximum final KCl-induced contraction in controls was
less than 90% of the initial KCl response.
Chemicals
U46619, methylene blue, L-NAME, Rp-8-Br-PET-cGMPS,
and sodium nitroprusside were purchased from Sigma
Aldrich (Poole, Dorset, UK). All salts were purchased from
Lennox Laboratory Supplies (Dublin, Ireland). The silde-
nafil citrate was obtained from Pfizer Limited, UK (Sand-
wich, Kent).
Statistical Analysis
Data are presented as means ± SEM, with contractile
response to U46619 expressed in grams and relaxation
response to sildenafil citrate and sodium nitroprusside
expressed as a percentage of baseline submaximal contrac-
tion. Comparison between control and test rings wasReproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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made using two way repeated measures analysis of vari-
ance, with group and sildenafil/vehicle concentration as
factors. Between group analyses were restricted to compar-
isons relevant to our a priori hypotheses, and were made
using student's t testing with corrections for multiple com-
parisons. The null hypothesis was rejected for p < 0.05.
Results
Chorionic plate arterial rings were obtained from placen-
tae from 55 women ((median age, 26 years [range, 18–42
years]; median parity, 1 [range, 0–4]) following uncom-
plicated full term (median gestation 40 wks [range 38 –
41]) gestation, for these studies.
Characterization of phosphodiesterase-5 in chorionic 
arteries
Phosphodiesterase-5 mRNA is present in chorionic plate
arterial rings as demonstrated by RT-PCR. cDNA prepared
from RNA extracted from homogenized chorionic plate
arterial rings, and amplified by PCR using specific primers
for the phosphodiesterase-5 gene, and electrophoresed on
1% agarose, demonstrated a band for phosphodiesterase-
5 (Figure 2 Panel A).
The Phosphodiesterase-5 protein is present in chorionic
plate arterial rings as demonstrated by Western blot. SDS-
PAGE Western blot of protein samples from chorionic
plate arterial ring homogenates were demonstrated to spe-
cifically bind PDE-5 antibody (Figure 2 Panel B).
Fluorescent microscopy of paraffin embedded slices of
chorionic plate arterial rings demonstrated specific bind-
ing of PDE-5 primary antibodies within the cytoplasm of
cells in the muscle layer within the arterial ring section.
There is comparatively little staining for PDE-5 in the
endothelial layer (Figure 3 Panels A – D).
Sildenafil effects and mechanism of action
Stable and comparable gas tensions were maintained
throughout all experiments, and comparable baseline lev-
els of contractile responses were observed in all series.
Post-intervention responses to potassium chloride were
not different between the groups in any series.
Effects of sildenafil citrate on contractility of chorionic arterial rings
In Series 1, sildenafil citrate dose dependently dilated cho-
rionic arterial rings (n = 20 rings per group) following
U46619 pre-constriction. Mean relaxation increased from
1.6 ± 1.2% at 10-10 M, 11.1 ± 2.6% at 10-7 M to 82.7 ±
5.5% at 10-3 M (± SEM) sildenafil citrate (Figure 4 Panel
A). The concentration of sildenafil citrate that produced a
50% relaxation (EC50r) was 1.6 ± 0.4 × 10-4 M. Sildenafil
citrate resulted in significant vasodilation over control
conditions at concentrations at or greater than 1 × 10-8 M.
Role of cGMP on sildenafil citrate-induced chorionic arterial ring 
vasorelaxation
Series 2 examined the potential for incubation with
methylene blue (3 × 10-5 M), a direct inhibitor of cGMP,
to attenuate sildenafil citrate induced Vasorelaxation (n =
10 rings). There was minimal vasodilation in the rings
exposed to control conditions or methylene blue alone.
Methylene blue significantly attenuated the vasodilation
produced by sildenafil citrate (Figure 4Panel B), and sig-
nificantly increased the EC50r for sildenafil citrate (1.5 ±
0.5 versus 4.5 ± 0.4 × 10-4 M, P < 0.01). These findings
indicate a role for cGMP in mediating the vasodilation
produced by sildenafil citrate.
Panel A: Demonstration of PDE-5 mRNA in chorionic plate  arterial rings Figure 2
Panel A: Demonstration of PDE-5 mRNA in chori-
onic plate arterial rings. cDNA was prepared from RNA 
extracted from chorionic plate arterial rings, and amplified 
using specific primers for 400 bp regions of the indicated 
genes. PCR products were electrophoresed on 1% agarose. 
Panel B: Demonstration of PDE-5 protein in chorionic plate 
arterial rings. Human chorionic plate arterial rings homoge-
nates, representing various amounts of protein, were exam-
ined by SDS-PAGE Western blot for the presence of PDE-5.Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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Immunohistochemical demonstration of the localization of PDE-5 protein in chorionic plate arterial rings Figure 3
Immunohistochemical demonstration of the localization of PDE-5 protein in chorionic plate arterial rings. Hae-
matoxylin and eosin staining of a paraffin embedded 15 μm section from a chorionic plate arterial ring demonstrates the struc-
ture of the ring (Panel A). Subsequent images, enlarged from the section of the wall of this ring indicated by the rectangle, 
demonstrate nuclear staining with DAPI (Panel B), staining with PDE-5 primary and phycoerythrin labeled secondary (Sigma) 
antibodies (Panel C), and the superimposition of panels B and C to demonstrate the cytoplasmic location of PDE-5 (Panel D).Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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Panel A: Cumulative concentration-response curve for silde- nafil citrate from 10-10 M to 10-3 M compared to control  (vehicle) at a submaximal U46619 induced contraction Figure 4
Panel A: Cumulative concentration-response curve 
for sildenafil citrate from 10-10 M to 10-3 M compared 
to control (vehicle) at a submaximal U46619 induced 
contraction. *P < 0.05 compared to baseline. † P < 0.05 
compared to control. Panel B: Cumulative concentration-
response curve for sildenafil citrate from 10-7 M to 10-3 M 
compared to vehicle at a submaximal U46619 induced con-
traction, in the presence and absence of methylene blue. *P < 
0.05 compared to baseline. † P < 0.05 compared to sildenafil 
citrate.
Panel A: Cumulative concentration-response curve for silde- nafil citrate from 10-7 M to 10-3 M compared to vehicle at a  submaximal U46619 induced contraction, in the presence  and absence of cGMPS (3 × 10-6 M) Figure 5
Panel A: Cumulative concentration-response curve 
for sildenafil citrate from 10-7 M to 10-3 M compared 
to vehicle at a submaximal U46619 induced contrac-
tion, in the presence and absence of cGMPS (3 × 10-6 
M). Panel B: Cumulative concentration-response curve for 
sildenafil citrate from 10-7 M to 10-3 M compared to vehicle at 
a submaximal U46619 induced contraction, in the presence 
and absence of cGMPS (3 × 10-5 M). *P < 0.05 compared to 
baseline. † P < 0.05 compared to sildenafil citrate.Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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Series 3 examined the potential for direct inhibition of
the cGMP-dependent protein kinase to attenuate sildena-
fil citrate induced Vasorelaxation. In Series 3A, there was
minimal vasodilation in the rings exposed to control con-
ditions or Rp-8-Br-PET-cGMPS (3 μM) alone (n = 10
rings). Rp-8-Br-PET-cGMPS (3 × 10-6 M) did not modulate
the vasodilation produced by sildenafil citrate (Figure 5
Panel A). In Series 3B, again there was minimal vasodila-
tion in the rings exposed to control conditions or Rp-8-Br-
PET-cGMPS (3 × 10-5 M) alone (n = 10 rings). However
the higher concentration of Rp-8-Br-PET-cGMPS (3 × 10-5
M) significantly attenuated the vasodilation produced by
sildenafil citrate (Figure 5 Panel B) and increased the
EC50r for sildenafil citrate (3.3 ± 0.6 versus 24.7 ± 15.0 ×
10-4 M, P < 0.01). These findings indicate that the cGMP
dependent effect of sildenafil citrate in producing vasodi-
lation in the feto-placental circulation is mediated via the
cGMP-dependent protein kinase.
Role of nitric oxide on the sensitivity of chorionic arterial rings to the 
vasoactive effect of sildenafil citrate
Series 4A examined the potential for incubation with L-
NAME, a non-specific inhibitor of nitric oxide synthase, to
attenuate sildenafil citrate induced Vasorelaxation (n = 10
rings). There was minimal vasodilation in the rings
exposed to control conditions or L-NAME alone. L-NAME
did not modulate the vasodilation produced by sildenafil
citrate (Figure 6 Panel A).
Series 4B examined the potential for sildenafil to alter
vessel sensitivity to exogenous NO (n = 10 rings). SNP
dose dependently dilated pre-constricted rings, with a
maximal relaxation of 11.3% ± 3.5% (mean ± SEM) at 10-
8 M SNP and 100% ± 4.2% at 10-7 M SNP. At lower SNP
concentrations (10-9 to 10-8 M), sildenafil citrate signifi-
cantly, and dose dependently, increased the responsive-
ness of the rings to SNP (Figure 6Panel B).
Discussion
Our results demonstrate the presence of phosphodieste-
rase-5 in the human feto-placental circulation and further
demonstrate that sildenafil citrate is a vasodilator in this
circulation. The vasodilatory effects of sildenafil citrate are
mediated by via cGMP pathway, and involve an increase
in vascular sensitivity to NO. These results are of clear sig-
nificance given the growing role for sildenafil citrate for
the treatment of pulmonary hypertension in pregnancy.
In addition, these findings provide support for the
hypothesis that sildenafil citrate may have a role in aug-
menting feto-placental blood flow in the setting of pla-
cental vascular insufficiency and pre-eclampsia [12].
Sildenafil citrate is increasingly used in the pregnant
patient for the treatment of pulmonary hypertension in
pregnancy, a disease associated with poor maternal [5]
and fetal outcome [18]. Its safety and efficacy in this set-
ting, combined with its lack of teratogenic or fetotoxic
effects even at very high dosages in animal studies, mean
that its use for the treatment of pulmonary hypertension
in pregnancy is likely to increase [11]. Sildenafil citrate
also causes relaxation of the human myometrium [19,20],
and reduces intra-uterine pressures during preterm labor
in rodents [21] and may therefore have a role as a tocolytic
agent in the setting of premature labor. In addition, silde-
nafil citrate increases uteroplacental blood flow, and may
have a role in the treatment of intra-uterine growth retar-
dation. Sildenafil citrate improves the endothelial func-
tion of myometrial vessels from women whose
pregnancies are complicated by intrauterine growth
restriction [22]. Sildenafil enhanced fetal tolerability to
induced intrapartum asphyxia, and increased fetal weight
Panel A: Cumulative concentration-response curve for silde- nafil citrate from 10-7 M to 10-3 M compared to vehicle at a  submaximal U46619 induced contraction, in the presence  and absence of L-NAME Figure 6
Panel A: Cumulative concentration-response curve 
for sildenafil citrate from 10-7 M to 10-3 M compared 
to vehicle at a submaximal U46619 induced contrac-
tion, in the presence and absence of L-NAME. *P < 
0.05 compared to baseline. Panel B: Histogram of concen-
tration dependent relaxation for sodium nitroprusside in the 
presence of increasing concentrations of sildenafil citrate. †P 
< 0.05 compared to control.Reproductive Biology and Endocrinology 2009, 7:34 http://www.rbej.com/content/7/1/34
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in guinea pigs [23]. Sildenafil increases rodent fetal size in
the setting of hypoxia, induced by exposure of pregnant
rats to environmental hypoxia, although this was not seen
in the non-hypoxic setting [24].
The effects of sildenafil in the feto-placental circulation
have not been characterized. In the uterine circulation,
sildenafil citrate causes uterine artery vasodilation in non-
pregnant females [25], and produces vasodilation in small
myometrial arteries in women whose pregnancies are
complicated by fetal growth retardation [22]. Should
sildenafil citrate possess a similar vasodilatory effect in the
feto-placental circulation, this would significantly
enhance its therapeutic potential in the setting of placen-
tal insufficiency. It might also explain, in part, the benefi-
cial effects seen on fetal growth in experimental studies of
intrapartum asphyxia [23] and hypoxia [24]. While pla-
cental transfer of sildenafil citrate has not been quantified,
due to its chemical characteristics it is likely to easily cross
the placenta into the fetus.
Phospohdiesterase-5 has previously been demonstrated
in the ovine feto-placental circulation [26]. In our study,
we demonstrate the presence of mRNA and protein for
phosphodiesterase-5, and confirm its presence immuno-
histochemically, in the human fetal placental circulation.
This finding provided the rationale for our subsequent
pharmacologic studies. These demonstrate that sildenafil
citrate dose dependently vasodilates pre-constricted chor-
ionic plate rings at concentrations of 1 × 10-8 M and
greater. Pharmacokinetic data suggest that a 100 mg oral
dose of sildenafil citrate produces a plasma concentration
in excess of 1 × 10-7 M for 4 to 5 hours [27]. In addition,
the peak plasma concentration achieved after an oral dose
of sildenafil citrate 100 mg is 440 ng/ml, which equates to
1.5 × 10-6 M [27]. Therefore, sildenafil citrate produced
vasodilation in the feto-placental circulation at clinically
relevant concentrations.
Our finding that Methylene blue, which is a direct inhibi-
tor of cGMP, attenuated sildenafil citrate vasodilation,
demonstrates that sildenafil citrate vasodilation is medi-
ated via a cGMP dependent mechanism in this circula-
tion. The direct cGMP dependant protein kinase inhibitor
Rp-8-Br-PET-cGMPS (3 × 10-5 M) significantly attenuated
the vasodilation produced by sildenafil citrate, indicating
that sildenafil citrate vasodilation is mediated via the
cGMP-dependent protein kinase. Our finding that L-
NAME did not inhibit sildenafil citrate vasodilation, indi-
cates that de novo nitric oxide generation is not required to
produce sildenafil citrate mediated vasorelaxation in this
circulation. Conversely, sildenafil citrate potentiated the
vasodilation produced by sodium nitroprusside, an exog-
enous NO donor, indicating that sildenafil citrate
increased NO sensitivity.
There are a number of aspects of this study that indicate
the need for caution prior to extrapolation to the clinical
scenario. Firstly, these studies are conduced in chorionic
plate arteries. Characterization of effects of sildenafil cit-
rate on smaller vessels in the feto-placenta circulation (i.e.
placental resistance arteries) is also required. Secondly,
umbilical cord artery samples were obtained from healthy
parturients. Characterization of the effects of sildenafil cit-
rate in the setting of pulmonary hypertension of preg-
nancy, in which fetal hypoxia may be more frequent,
would add further useful information. Finally, there are
limitations in extrapolating from in vitro experiments to
the in vivo situation, but the experiments conducted here
represent a reliable and valid in vitro model for these vas-
cular preparations.
In conclusion, our results demonstrate that phosphodi-
esterase-5 is present in the feto-placental circulation, and
that sildenafil citrate is a vasodilator in this circulation.
The vasodilatory effects of sildenafil citrate are mediated
via a cGMP dependent mechanism, which involves in
increase in vascular sensitivity to NO. These results are of
clear significance given the growing role for sildenafil cit-
rate for the treatment of pulmonary hypertension in preg-
nancy and may indicate a potential role for sildenafil
citrate in augmenting feto-placental blood flow in the set-
ting of placental vascular insufficiency.
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